Organization
Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases
Pfizer, Flagship Pioneering, Quotient Therapeutics, cardiovascular diseases, renal diseases, somatic genomics, drug development, partnership
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development
MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush
MBX Biosciences, IPO, NASDAQ, peptide therapeutics, biotech, public offering
BridgeBio Unveils GondolaBio with $300M Investment, Transfers Key Programs to Joint Venture
BridgeBio, GondolaBio, Joint Venture, $300M Investment, Genetic Therapies, Biopharma Startup
Walgreens and BARDA Collaborate on $100M Decentralized Clinical Trials Initiative
Walgreens, BARDA, Decentralized Clinical Trials, $100M Partnership, Healthcare Research
AstraZeneca Wins Patent Infringement Case Against Pfizer, Vacates $107.5M Jury Award
AstraZeneca, Pfizer, patent infringement, jury award, US court
Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment
Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring
Gene Therapy Pioneer Jim Wilson Departs UPenn to Launch Two New Biotech Companies
Jim Wilson, UPenn, gene therapy, biotech companies, GEMMA Biotherapeutics, Franklin Biolabs
Biogen Lifts Outlook as Leqembi Sales Accelerate in Q2
Biogen, Leqembi, Q2 earnings, Alzheimer’s drug, cost cuts, profit outlook